Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy.
Children with Philadelphia (Ph) chromosome positive (+) acute lymphoblastic leukemia (ALL) represent a subgroup at very high risk for treatment failure. This study included 1322 children enrolled between 1988 and 1994 on CCG risk-adjusted studies for ALL who had centrally reviewed cytogenetic data. Thirty patients had a t(9;22) and are referred to as Ph+; 1292 were Ph-. 23 of these 30 patients were treated on the CCG-1882 high risk ALL protocol. The event-free survival (EFS) outcome in CCG-1882 was significantly worse for Ph+ compared with Ph- patients, with 4-year estimates of 11.3% (SD = 9.8%) and 73.4% (SD = 2.3%), respectively (p < 0.0001).
Uckun
F M
FM
Children's Cancer Group ALL Biology Reference Laboratory and Parker Hughes Cancer Center, Hughes Institute, St. Paul, MN 55113, USA.
Nachman
J B
JB
Sather
H N
HN
Sensel
M G
MG
Kraft
P
P
Steinherz
P G
PG
Lange
B
B
Hutchinson
R
R
Reaman
G H
GH
Gaynon
P S
PS
Heerema
N A
NA
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018572:Disease-Free Survival; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D007223:Infant; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D016896:Treatment Outcome
D000970:Antineoplastic Agents